Purdue University. US: FAST BioMedical Inc.
announces the conclusion of a Phase II clinical trial for a technology
designed to provide timely, precise and convenient plasma volume and
kidney function measurements. This is especially useful for patients
undergoing major surgery and for the critically ill.
"The technology could allow physicians to determine plasma volume and
kidney function more precisely and timely than the current standards of
care," said Joe Muldoon, FAST BioMedical CEO. "Primary market research
shows us that this could be a substantial game changer in critical
care."
The American College of Cardiology and American Heart Association
recommend assessing volume status in all heart failure patients. Even a
10 percent increase in blood volume has been directly linked to worse
patient outcomes and longer hospital stays for heart failure patients.
The association reports that a third of all ICU patients has an episode
of blood volume resuscitation, and a quarter of all ICU patients suffer
from acute kidney injury.
FAST BioMedical's patented technology provides plasma volume in 15
minutes, a screening kidney function level in 60 minutes and a measured
kidney function in 120 minutes. Currently available methods include a
combination of surrogate measurements that can be invasive,
time-consuming and provide inconclusive results.
Muldoon added that the technology has potential to aid in other health care settings including:
*Organ transplant donor selection and management of anti-rejection drug dosing.
*Sepsis identification and management...
*Acute respiratory distress syndrome.
*Chronic kidney disease.
*Congestive heart failure.
The company has raised $20 million to date to advance and
commercialize the innovation. The Purdue Foundry Investment Fund
provided $200,000 to help advance the innovation as part of a matching
program established in 2014 through a partnership between the Purdue
Research Foundation and Cook Medical.
FAST BioMedical has completed development work with Indiana
University School of Medicine, Purdue University and Rose-Hulman and has
been financially supported by Elevate Ventures, Indiana Economic
Development Corporation, BioCrossroads, VisionTech, Rose-Hulman Ventures
and the National Institutes of Health.
About FAST BioMedical
FAST BioMedical is a private, Indianapolis-based, clinical stage
medical technology company focusing on development and commercialization
of a patented technology for quantifying Plasma Volume and Kidney
Function in a clinically actionable time-frame. FAST BioMedical’ s
technology has completed a Phase II clinical trial and could have a
significant impact on the treatment
of critically ill patients, those undergoing major surgery, and those
at risk of acute kidney injury (AKI) and chronic kidney disease (CKD).